Sugi Predict

Sugi Predict / Targets / POLB

POLB

DNA polymerase beta · P06746 · POLB on Sugi Atlas →

3,039,996 patent compounds predicted against POLB, 1,754,129 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Cefazolin Cefazolin (SCHEMBL2841) 0.71 9/20
Cefazolin Cefazolin (SCHEMBL2842) 0.71 9/20
SCHEMBL4112 SCHEMBL4112 0.53 5/20
Bisnafide Bisnafide (SCHEMBL3726) 0.48 5/20
SCHEMBL256 SCHEMBL256 0.74 4/20
Resazurin Resazurin (SCHEMBL6338) 0.70 4/20
SCHEMBL622 SCHEMBL622 0.66 4/20
SCHEMBL670 SCHEMBL670 0.60 4/20
SCHEMBL584 SCHEMBL584 0.56 4/20
SCHEMBL5946 SCHEMBL5946 0.56 4/20
SCHEMBL6960 SCHEMBL6960 0.56 4/20
SCHEMBL6053 SCHEMBL6053 0.55 4/20
SCHEMBL3446 SCHEMBL3446 0.54 4/20
Meclocycline Meclocycline (SCHEMBL3445) 0.53 4/20
SCHEMBL8115 SCHEMBL8115 0.50 4/20
SCHEMBL701 SCHEMBL701 0.49 4/20
SCHEMBL598 SCHEMBL598 0.48 4/20
Daunorubicin Daunorubicin (SCHEMBL4444) 1.00 3/20
Daunorubicin Daunorubicin (SCHEMBL4445) 1.00 3/20
Safingol Safingol (SCHEMBL6772) 1.00 3/20

Clinical trials — most relevant to POLB by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
PREventing Progression of Adipose Tissue Redistribution PHASE4COMPLETED
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection PHASE3UNKNOWN
Intracameral Antibiotic Safety Study PHASE3SUSPENDED
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) PHASE3WITHDRAWN
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer PHASE2COMPLETED
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer PHASE2UNKNOWN
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) PHASE2RECRUITING
Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma PHASE2COMPLETED
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability PHASE2ACTIVE_NOT_RECRUITING
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer PHASE2ACTIVE_NOT_RECRUITING
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment PHASE2ACTIVE_NOT_RECRUITING
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib PHASE2COMPLETED
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) PHASE2UNKNOWN
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors PHASE1COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers PHASE1COMPLETED
Spironolactone and XPB-1 Integrity in the TFIIH Complex nanENROLLING_BY_INVITATION
Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML nanRECRUITING
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission. nanUNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer nanUNKNOWN
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC nanUNKNOWN
Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer nanNOT_YET_RECRUITING
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility nanRECRUITING
Cohort of Tumors With POLE/D1 Mutation nanRECRUITING
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease nanCOMPLETED
Choroid Plexus Dysfunction in Neurological Diseases nanRECRUITING
Chronic Cough and CANVAS (Cerebellar Ataxia With Neuropathy and Bilateral Vestibular Areflexia Syndrome) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a POLB binder may also engage these)

ProteinNameSimilarity
Q27958 — 0.999 Q27958 →
P06766 — 0.999 P06766 →
Q8K409 — 0.996 Q8K409 →
O57383 — 0.992 O57383 →
Q6DRD3 — 0.981 Q6DRD3 →
Q80Z29 — 0.940 Q80Z29 →
Q5R8T5 — 0.939 Q5R8T5 →
Q2RAK2 — 0.939 Q2RAK2 →
Q9SGY2 — 0.939 Q9SGY2 →
YARS1 Tyrosine--tRNA ligase, cytoplasmic 0.939 landscape →
Q94899 — 0.937 Q94899 →
A0JN39 — 0.936 A0JN39 →
Q4KM49 — 0.936 Q4KM49 →
Q2QZ86 — 0.936 Q2QZ86 →
Q07346 — 0.936 Q07346 →
B8BJ39 — 0.935 B8BJ39 →
O22718 — 0.935 O22718 →
Q2QXR8 — 0.935 Q2QXR8 →
O09171 — 0.934 O09171 →
Q5RFG2 — 0.933 Q5RFG2 →
Q91WQ3 — 0.933 Q91WQ3 →
O80526 — 0.933 O80526 →
Q5R648 — 0.933 Q5R648 →
Q2QNG7 — 0.932 Q2QNG7 →
NAMPT Nicotinamide phosphoribosyltransferase 0.932 landscape →
Q5RDD3 — 0.932 Q5RDD3 →
Q6P0H6 — 0.932 Q6P0H6 →
Q8W4M5 — 0.932 Q8W4M5 →
Q5R922 — 0.932 Q5R922 →
Q68FS2 — 0.931 Q68FS2 →